Armistice Capital’s Charles River Laboratories CRL Stock Holding History

Armistice Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$204K	Buy	+900	New	+$160K	﹤0.01%	295
2025 Q4	–	Sell	-1,932	Closed	-$302K	–	397
2025 Q3	$302K	Buy	+1,932	New	+$307K	﹤0.01%	246
2024 Q3	–	Sell	-119,071	Closed	-$24.6M	–	275
2024 Q2	$24.6M	Buy	119,071 +49,189	+70%	+$11.1M	0.31%	57
2024 Q1	$18.9M	Buy	69,882 +33,882	+94%	+$8.09M	0.25%	70
2023 Q4	$8.51M	Sell	36,000 -120,000	-77%	-$23.6M	0.12%	100
2023 Q3	$30.6M	Buy	+156,000	New	+$32M	0.47%	43

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Armistice Capital's CRL Position: Q2 2026 in Review

Armistice Capital opened a new position in Charles River Laboratories (CRL) in Q2 2026: 900 shares worth $204K. The stake represents ﹤0.01% of the portfolio and ranks #295 among its holdings. This is a return to the name: Armistice Capital previously reported a position in CRL as recently as Q3 2025.

Armistice Capital first reported a position in CRL in Q3 2023 and has held it in 6 quarters since. The position peaked at $30.6M in Q3 2023. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Armistice Capital held 900 shares of Charles River Laboratories worth $204K as of Q2 2026.
Charles River Laboratories was a new Armistice Capital position in Q2 2026.
Charles River Laboratories made up ﹤0.01% of Armistice Capital's portfolio in Q2 2026, its #295 holding.
Armistice Capital first reported a position in Charles River Laboratories in Q3 2023 and has held it in 6 quarters since.
Armistice Capital's Charles River Laboratories position peaked at $30.6M in Q3 2023.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.